Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (September 2020)

51 slides from Marinus Pharmaceuticals's investor presentation, Sep 14, 2020

  1. Slide 1: Corporate Overview 2020

    NASDAQ: MRNS @MarinusPharma Corporate Overview 2020

  2. Slide 2: Safe Harbor Statement

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Safe Harbor Statement 2 To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management m

  3. Slide 3: Ganaxolone Targets Synaptic & Extrasynaptic GABA A Receptors

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone (GNX) Targets Synaptic & Extrasynaptic GABA A Receptors 3 Ganaxolone a positive allosteric GABA A receptor modulator with a well - defined MOA designed to treat patients suffering from epilepsy and neuropsychiatric disorders. GNX is des

  4. Slide 4: Marinus Corporate Strategy

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Evaluation of IV and Oral Opportunities Building Upon Status Epilepticus (SE) Maximizing Value for Orphan Epilepsies • Expand clinical opportunities from refractory status epilepticus (RSE) to broader SE market • Initiate commercial plan • Create

  5. Slide 5: Ganaxolone Development Pipeline

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 5

  6. Slide 6: Status Epilepticus Indication

    Status Epilepticus Indication

  7. Slide 7: Status Epilepticus: Definition and Epidemiology

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus (SE): Definition and Epidemiology Background • Continuous seizures lasting >5 min • Heterogenous patient population with various etiologies, including glioblastoma, vascular disease, encephalitis, drug or alcohol withdrawal or o

  8. Slide 8: Goals of a New Therapy for the Treatment of SE

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Goals of a New Therapy for the Treatment of SE 8 Benzodiazepine Administered Medically induced Coma Established Status Epilepticus (ESE) 1 st line 2 nd line IV AED’s (antiepileptic drugs) 3 rd line IV Anesthetics Super Refractory Status Epilepticu

  9. Slide 9: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain 1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes 2 EEG bispectral index in healthy volunteers follow

  10. Slide 10: Phase 2 SE Trial Design

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper Phase 2 SE Trial Design 10 Diagnosis of convulsive or non - convulsive SE Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics Bolus plus continuous infusion 2 - 4

  11. Slide 11: Patient Demographics of Phase 2 Trial

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Patient Demographics of Phase 2 Trial 11 • 8 males, 9 females • Mean age: 57 years old (range: 23 - 88) 5 (29%) CSE, 11 (65%) NCSE, 1 (6%) CSE → NCSE 7 (41%) yes, 10 (59%) no 17 patients enrolled Types of SE History of Epilepsy Mean # of failed 2n

  12. Slide 12: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status - free through 24 hours from infusion initiation (investigator determ

  13. Slide 13: PK/PD Relationship and Rationale for Target Dose

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I PK/PD Relationship and Rationale for Target Dose 13 Seizure Burden Reduction Occurred Rapidly in All Dose Groups Modeled PK Curves for All Dose Groups High Dose Achieves Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduc

  14. Slide 14: IV Ganaxolone Safety Summary

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I IV Ganaxolone Safety Summary 14 Intubation: 9 patients were not intubated upon enrollment. Of these, 6 remained intubation - free during the entire ganaxolone treatment perio d Data presented at AES 2019 AE: adverse event / SAE: serious adverse ev

  15. Slide 15: Overview of U.S. Phase 3 SE Trial Design

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Overview of U.S. Phase 3 SE Trial Design Trial design • Randomized, placebo - controlled (adjunctive to standard - of - care) clinical trial Target patient population • Status epilepticus patients (n=124) who have failed benzodiazepines and ≥ 2 IV

  16. Slide 16: SE Phase 3 Clinical Planning

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I SE Phase 3 Clinical Planning 16 • 1:1 randomized, double - blind, placebo - controlled trial • Failure of a benzodiazepine and 2 second - line IV AEDs • 3 - minute bolus, 36 - hour infusion, 12 - hour taper • Approx. 125 randomized patients • 80 -

  17. Slide 17: RAISE Trial Sites Standard of Care Progression to IV Anesthesia

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I RAISE Trial Sites Standard of Care Progression to IV Anesthesia • Surveyed PI’s at selected RAISE Trail sites to learn more about their standard of care natural history progression to IV anesthesia following the failure of one versus more than one

  18. Slide 18: BARDA Contract – Refractory Status Epilepticus

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I BARDA Contract – Refractory Status Epilepticus 18 Key Contract Parameters • BARDA to contribute $21 million in base contract to support the Phase 3 clinical trial in RSE and preclinical studies of ganaxolone in nerve agent exposure animal models.

  19. Slide 19: Quantifying the Significant Clinical and Economic Burden of SE

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Quantifying the Significant Clinical and Economic Burden of SE The Phase 3 trial of ganaxolone in refractory SE aims to demonstrate rapid onset of action capable of preventing escalation to IV anesthetics. Treatment with IV anesthetics has been re

  20. Slide 20: SE Severity Correlates with Clinical Consequences & Increased Healthcare Utilization

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I SE Severity Correlates with Clinical Consequences & Increased Healthcare Utilization Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (> 1 IV AED) Cohort 3 ( ≥ 1 IV anesthetic) All Unique SE patient encounter, N (%) 14,694 (33.4

  21. Slide 21: Clinical Opportunities Throughout the SE Continuum

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Clinical Opportunities Throughout the SE Continuum Benzodiazepine Administered Medically induced Coma Established Status Epilepticus (ESE) 1 st line 2 nd line IV AED’s 3 rd line IV Anesthetics Super Refractory Status Epilepticus (SRSE) Refractory

  22. Slide 22: Ganaxolone Formulation Work in Progress for Second Generation Candidate

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Formulation Work in Progress for Second Generation Candidate Step down IV to oral Pediatric Dosing IV Dosing Oral Dosing • Exploring opportunities to improve bioavailability and PK profile • Allow expansion into new indications, and cre

  23. Slide 23: Genetic Epilepsy Franchise

    Genetic Epilepsy Franchise \ 4 E:

  24. Slide 24: CDKL5 Deficiency Disorder

    CDKL5 Deficiency Disorder

  25. Slide 25: CDKL5 Deficiency Disorder (CDD)

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Cause Mutation of the cyclin - dependent kinase - like 5 ( CDKL5 ) gene, located on the X chromosome Symptoms Early - onset, treatment refractory seizures, & severe neuro - developmental delay Most can’t walk, talk or care for themselves Suffer fr

  26. Slide 26: Global Phase 3 Pivotal Trial Design

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Global Phase 3 Pivotal Trial Design 26 Baseline 6 weeks Historical Control 8 weeks Double - Blind Phase Open - Label Phase Maintenance 13 weeks Titration 4 weeks Titration 4 weeks Open - Label Phase Trial Details • Evaluated the use of oral ganaxo

  27. Slide 27: Subject Baseline Clinical Characteristics & Prior/Concomitant Medications

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Subject Baseline Clinical Characteristics & Prior/Concomitant Medications 27 Characteristic Placebo (n=51) Ganaxolone (n=50) Total (n=101) Baseline Primary Seizure Frequency, per 28 days (median, min - mix ) 50.0, 0.7 – 1021.3 57.3 5.5 – 651.3 - N

  28. Slide 28: Ganaxolone Achieves Primary Efficacy Endpoint in the Marigold Study

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Achieves Primary Efficacy Endpoint in the Marigold Study 28 Ganaxolone Placebo 0 10 20 30 40 M e d i a n P e r c e n t R e d u c t i o n 2 8 - d a y F r e q u e n c y o f M a j o r M o t o r S e i z u r e s 32.2% 4.0% = 29.7%* p = 0.002

  29. Slide 29: Caregiver Global Impression of Change in Seizure Intensity/Duration

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Caregiver Global Impression of Change in Seizure Intensity/Duration 29

  30. Slide 30: Marigold Cumulative Response Curve

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Marigold Cumulative Response Curve 30 0% 5 10 15 20 25 30 35 40 45 50 0 20 40 60 80 % Reduction in Major Motor Seizure Frequency % o f P a t i e n t s Ganaxolone Placebo * * * * * * * * * *p < 0.05 *Fisher's Exact Test

  31. Slide 31: Phase 3 Safety Summary

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Safety Summary 31 Treatment Emergent Adverse Events (TEAE) Preferred Term Placebo (n=51) Ganaxolone (n=50) Any TEAE, n (%) 45 (88.2) 43 (86.0) Somnolence 8 (15.7) 18 (36.0) Pyrexia 4 (7.8) 9 (18.0) Upper Respiratory Tract Infection 3 (5.9)

  32. Slide 32: Potential for Durability Differentiation in the Treatment of CDD Patients

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Potential for Durability Differentiation in the Treatment of CDD Patients • Vast majority of patients with CDD do not have long - lasting response rates to anti - epileptics 1 • In Phase 2 trial 4 of 7 patients entered the extension period • Ganax

  33. Slide 33: Commercialization Preparedness

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Commercialization Preparedness Executing research with Payers and Physicians around TPP / Value Proposition Identifying organizational needs for field resources, systems and processes Developing plans to scale up Advocacy, Scientific Affairs and C

  34. Slide 34: Addressable Patient Population

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I ~48,900 Rare Epilepsy ~ 4,400 CDKL 5 Patients ~ 20,000 TSC patients Addressable Patient Population 20 - 40% refractory 4 Phase 2 (TSC) 40,000 patients 2 50 - 60% refractory 3 Phase 3 (CDKL 5) ~5,500 patients 1 80 - 90% refractory 3 ~163,000 5 Rare

  35. Slide 35: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex

  36. Slide 36: Allo-S as Potential Biomarker Across Various Genetic Epilepsies

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Allo - S as Potential Biomarker Across Various Genetic Epilepsies 36 Scientific literature associates genetic orphan epilepsies with neurosteroid imbalances Marinus has identified abnormal neurosteroid levels in several patient subtypes These find

  37. Slide 37: Tuberous Sclerosis Complex

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Cause Defect or mutation of TSC1 and/or TSC2 genes Symptoms Benign tumors, seizures, cognitive impairment, behavioral problems, skin abnormalities Prevalence ~25K - 40K refractory TSC patients in the U.S.* Treatments Limited approved treatments Me

  38. Slide 38: Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone • Epilepsy present in ~90% of individuals affected with TSC • Existing treatments fail to control seizures in ~60% of individuals with TSC - associated epilepsy • Uncontrolled seiz

  39. Slide 39: TSC Phase 2 Open-Label Clinical Trial Design

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I PART A PART B Base (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Open - Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol TSC - Phase 2 Open - Label Clinical Trial Design • n = 30 •

  40. Slide 40: PCDH19 Related Epilepsy

    PCDH19 Related Epilepsy

  41. Slide 41: PCDH19-Related Epilepsy

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Cause Inherited mutation of protocadherin 19 ( PCDH19 ) gene. Located on X chromosome Symptoms Early - onset seizures, cognitive and sensory impairment, and psychiatric and behavioral disorders. Seizures last from days to weeks; sensitive to fever

  42. Slide 42: Seizure Reduction in PCDH19-RE Phase 2 Trial in Patients with Low Allo Levels

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Seizure Reduction in PCDH19 - RE Phase 2 Trial in Patients with Low Allo Levels • 25% decrease in median seizure frequency reported in Phase 2 (n=11) • Stratification of patients by baseline plasma Allo levels identifies a subpopulation with expec

  43. Slide 43: Biomarker Stratified Proof of Concept Study in PCDH19

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Biomarker Stratified Proof of Concept (POC) Study in PCDH19 43 Trial Details • Ages 1 - 17 with 8 or more seizures in 8 weeks, failed 2 or more AEDs • Expect to complete double - blind portion of the trial with ~20 - 22 patients • Stratify patient

  44. Slide 44: Intellectual Property

    Intellectual Property

  45. Slide 45: Multiple Layers Of Potential Protection

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Patent Expected Patent Life Synthesis patents issued in Australia, Canada, China, Europe, Hong - Kong, India, Israel, Japan, Mexico, New Zealand, South Korea & U.S. 2030 IV formulations containing exclusively in - licensed proprietary Captisol ® p

  46. Slide 46: Thank You

    Thank You

  47. Slide 47: Appendix

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Appendix 47

  48. Slide 48: Details on Baseline Patient Characteristics for Phase 2 SE Trial

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I 48 NCSE: Non - convulsive status epilepticus CSE: Convulsive status epilepticus LAC: Lacosamide LEV: Levetiracetam LOR: Lorazepam PHT: Phenytoin fPHT: Fosphenytoin VPA: Valproic Acid Details on Baseline Patient Characteristics for Phase 2 SE Trial

  49. Slide 49: HEOR Opportunities to Expand Potential Value Proposition of Ganaxolone in SE

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I 49 HEOR Opportunities to Expand Potential Value Proposition of Ganaxolone in SE Quantify total cost of care in SE patients following hospital discharge • Many patients were discharged to long - term care or skilled nursing facilities and correlate

  50. Slide 50: Subject Baseline Demographics & Country Enrollment in CDD Trial

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Subject Baseline Demographics & Country Enrollment in CDD Trial 50 Demographic Placebo (n=51) Ganaxolone (n=50) Total (n=101) Age, median 7.0 5.0 6.0 Gender, n (%) Male 10 (19.6) 11 (22.0) 21 (20.8) Female 41 (80.4) 39 (78.0) 80 (79.2) Ethnicity,

  51. Slide 51: Percent Reductions in Major Motor Seizure Frequency

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Percent Reductions in Major Motor Seizure Frequency 51 25% 50% 75% 0 20 40 60 80 100 Reduction in Major Motor Seizure Frequency % o f P a t i e n t s Ganaxolone Placebo 57.1% 23.5% 24.5% 9.8% 10.2% 3.9% p=0.064* *Fisher's Exact Test p=0.001*

Marinus Pharmaceuticals — Investor Presentation (September 2020) on 6ix